IOVANCE BIOTHERAPEUTICS, INC. Fair Value of Assets Acquired
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Fair Value of Assets Acquired of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueOfAssetsAcquired · last filed 2026-02-24
- IOVANCE BIOTHERAPEUTICS, INC. fair value of assets acquired for the quarter ending 2024-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. fair value of assets acquired for the quarter ending 2023-12-31 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. fair value of assets acquired for the quarter ending 2023-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. fair value of assets acquired for the quarter ending 2022-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. fair value of assets acquired for fiscal 2023 was $222.64M.
| Period end | Fair Value of Assets Acquired 3 month | Fair Value of Assets Acquired 6 month | Fair Value of Assets Acquired 9 month | Fair Value of Assets Acquired 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $222.64M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $222.64M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $222.64M 10-Q · filed 2024-08-08 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |